We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+11.72%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.39B
AUM Growth
-$174M
Cap. Flow
-$28.5M
Cap. Flow %
-0.84%
Top 10 Hldgs %
46.4%
Holding
115
New
19
Increased
20
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$127M
2
ACLX
Arcellx
ACLX
+$37.7M
3
SNY icon
Sanofi
SNY
+$37.4M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$37M
5
APLS
Apellis Pharmaceuticals
APLS
+$32M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$109M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$50.4M
3
VRNA
Verona Pharma
VRNA
+$46.4M
4
ALBO
Albireo Pharma Inc
ALBO
+$38M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
2 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VBIV
51
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$15.9M 0.47%
1,744,500
– –
RCKT icon
52
Rocket Pharmaceuticals
RCKT
$343M
$14.9M 0.44%
867,732
-210,472
-20% -$4.12M
VKTX icon
53
Viking Therapeutics
VKTX
$3.88B
$14.5M 0.43%
+871,747
New +$9M
MIRM icon
54
Mirum Pharmaceuticals
MIRM
$6.56B
$14.4M 0.43%
+601,566
New +$13.7M
RAIN
55
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$14.4M 0.43%
1,648,215
-835,404
-34% -$7.72M
AORT icon
56
Artivion
AORT
$1.34B
$14.2M 0.42%
1,085,860
– –
AXGN icon
57
Axogen
AXGN
$2.2B
$13.3M 0.39%
1,409,791
+21,665
+2% +$198K
ISRG icon
58
Intuitive Surgical
ISRG
$127B
$12.8M 0.38%
50,000
+10,000
+25% +$2.46M
ISEE
59
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$12.2M 0.36%
500,000
-87,400
-15% -$1.91M
LONA
60
LeonaBio Inc
LONA
$66.1M
$12M 0.35%
479,728
– –
CTKB icon
61
Cytek Biosciences
CTKB
$566M
$11.9M 0.35%
1,289,534
– –
PRTA icon
62
Prothena Corp
PRTA
$448M
$11.5M 0.34%
237,646
– –
TCMD icon
63
Tactile Systems Technology
TCMD
$618M
$10.5M 0.31%
+639,877
New +$8.91M
FUSN
64
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$10.4M 0.31%
+2,759,936
New +$10.9M
LRMR icon
65
Larimar Therapeutics
LRMR
$377M
$10.3M 0.31%
2,280,709
-579,291
-20% -$3.03M
NBIX icon
66
Neurocrine Biosciences
NBIX
$18.2B
$10.1M 0.3%
100,050
– –
BMEA icon
67
Biomea Fusion
BMEA
$88.2M
$10.1M 0.3%
+325,000
New +$4.04M
MORF
68
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$9.66M 0.29%
256,737
-106,460
-29% -$3.92M
CMAX
69
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$9.55M 0.28%
119,201
+14,894
+14% +$1.74M
TYRA icon
70
Tyra Biosciences
TYRA
$1.85B
$7.95M 0.23%
494,403
– –
XBI icon
71
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$7.62M 0.23%
+100,000
New +$8.3M
BLPH
72
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$7.34M 0.22%
+930,000
New +$3.24M
HLVX
73
DELISTED
HilleVax
HLVX
$6.71M 0.2%
406,024
– –
CABA icon
74
Cabaletta Bio
CABA
$427M
$5.99M 0.18%
724,777
+407,323
+128% +$3.81M
AVDL
75
DELISTED
Avadel Pharmaceuticals
AVDL
$5.4M 0.16%
+590,000
New +$4.85M
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Perceptive Advisors held 115 positions worth $3.39B, down 4.9% from $3.56B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors's Q1 2023 filing shows 19 new, 20 increased, 20 reduced and 16 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 2,169,276 shares worth $197M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $109M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

  • Perceptive Advisors's largest Q1 2023 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 2,169,276 shares worth $197M.
  • Perceptive Advisors added most to Arcellx in Q1 2023, an estimated $37.7M increase.
  • Perceptive Advisors's biggest Q1 2023 reduction was Sarepta Therapeutics, cutting an estimated $50.4M.
  • Perceptive Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $109M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3.39B portfolio in Q1 2023.
  • Perceptive Advisors opened 19 new positions and closed 16 in Q1 2023.
  • Perceptive Advisors's portfolio value fell 4.9% quarter-over-quarter to $3.39B.

Based on Perceptive Advisors's 13F filing for Q1 2023, filed 15 May 2023.